NeurAxis Q4 2023 Earnings Report $2.40 0.00 (0.00%) (As of 12/20/2024 04:33 PM ET) Earnings History NeurAxis EPS ResultsActual EPS$0.29Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANeurAxis Revenue ResultsActual Revenue$0.53 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeurAxis Announcement DetailsQuarterQ4 2023Date4/16/2024TimeN/AConference Call ResourcesNRXS Earnings History 2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. NeurAxis Earnings HeadlinesNeurAxis files for secondary mixed shelf offeringDecember 13, 2024 | msn.comNeuraxis files $25M mixed securities shelfDecember 13, 2024 | markets.businessinsider.com2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.December 22, 2024 | Stansberry Research (Ad)Neuraxis files to sell 6.57M shares of common stock for holdersDecember 13, 2024 | markets.businessinsider.comNeurAxis, Inc.: NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic ConstipationDecember 10, 2024 | finanznachrichten.deNeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic ConstipationDecember 10, 2024 | markets.businessinsider.comSee More NeurAxis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NeurAxis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeurAxis and other key companies, straight to your email. Email Address About NeurAxisNeurAxis (NASDAQ:NRXS), a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.View NeurAxis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
